Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Eine Studie zu Buntanetap bei Teilnehmern mit PD

28. Oktober 2026 aktualisiert von: Annovis Bio Inc.

Eine offene klinische Studie zur Untersuchung der langfristigen Sicherheit von Buntanetap bei der Behandlung von Teilnehmern mit Parkinson-Krankheit

This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days.

Studienübersicht

Status

Rekrutierung

Intervention / Behandlung

Detaillierte Beschreibung

This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days. MMSE, MoCA, C-SSRS, and MDS-UPDRS will be assessed by clinicians who have successfully completed the requisite certifications/trainings for each assessment. Each participant shall be assessed by the same clinician throughout the study. Cohort 1 participants will stop standard of care Parkinson's medications 12h before baseline and annual clinical visits to ensure clinical OFF-state during visit. Cohort 2 participants will stop standard of care Parkinson's medications 12h before all clinic visits. The night before the baseline and annual clinic visits (or early termination visit), Cohort 2 participants will return DBS settings to their initial baseline settings.

Studientyp

Interventionell

Einschreibung (Geschätzt)

500

Phase

  • Phase 2
  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Studienorte

    • Alabama
      • Birmingham, Alabama, Vereinigte Staaten, 35233
        • Rekrutierung
        • University of Alabama at Birmingham
        • Kontakt:
        • Hauptermittler:
          • Natividad Stover, M.D.
    • Arizona
      • Sun City, Arizona, Vereinigte Staaten, 85351
        • Rekrutierung
        • Banner Sun Health Research Institute - Cleo Roberts Center for Clinical Research
        • Hauptermittler:
          • Sara Dhanani, M.D.
        • Kontakt:
    • California
      • Fountain Valley, California, Vereinigte Staaten, 92708
        • Rekrutierung
        • Parkinson's & Movement Disorder Institute (PMDI) - Orange County Office
        • Hauptermittler:
          • Daniel Truong, M.D.
        • Kontakt:
          • Evan Moreno-Davis
          • Telefonnummer: 714-378-5074
          • E-Mail: evan@pmdi.org
    • Colorado
      • Englewood, Colorado, Vereinigte Staaten, 80113
        • Rekrutierung
        • Cenexel Rocky Mountain Clinical Research
        • Kontakt:
        • Hauptermittler:
          • Meagen Salinas, M.D.
    • Connecticut
      • Stamford, Connecticut, Vereinigte Staaten, 06824
        • Rekrutierung
        • New England Institute for Clinical Research (Ki Health Partners)
        • Kontakt:
        • Hauptermittler:
          • Peter McAllister, M.D.
    • Florida
      • Aventura, Florida, Vereinigte Staaten, 33180
        • Rekrutierung
        • First Choice Neurology - Aventura Neurologic Associates
        • Hauptermittler:
          • Jonathan Cross, M.D.
        • Kontakt:
      • Daytona Beach, Florida, Vereinigte Staaten, 32117
        • Rekrutierung
        • Arrow Clinical Trials
        • Kontakt:
        • Hauptermittler:
          • David Billmeier, M.D.
      • DeLand, Florida, Vereinigte Staaten, 32720
        • Rekrutierung
        • Accel Clinical Sites-Georgia LLC dba Accel Research Sites-Lake Oconee CRU
        • Hauptermittler:
          • Bruce Rankin, D.O.
        • Kontakt:
      • Miami, Florida, Vereinigte Staaten, 33172
      • Miami, Florida, Vereinigte Staaten, 33015
        • Noch keine Rekrutierung
        • Ezy Medical Research Co.
        • Kontakt:
      • Ocala, Florida, Vereinigte Staaten, 34470
        • Rekrutierung
        • Renstar Medical Research
        • Hauptermittler:
          • Annette Nieves, M.D.
        • Kontakt:
      • Tampa, Florida, Vereinigte Staaten, 33613
        • Rekrutierung
        • University of South Florida (USF) - University of South Florida College of Medicine - Parkinson's Di
        • Kontakt:
        • Hauptermittler:
          • Robert Hauser, M.D., MBA
      • Winter Park, Florida, Vereinigte Staaten, 32789
    • Georgia
      • Decatur, Georgia, Vereinigte Staaten, 30030
        • Rekrutierung
        • iResearch Atlanta
        • Kontakt:
        • Hauptermittler:
          • Kimball Johnson, M.D.
    • Indiana
      • Indianapolis, Indiana, Vereinigte Staaten, 46256
        • Rekrutierung
        • Josephson Wallack Munshower Neurology, P.C.
        • Hauptermittler:
          • Kristi George, M.D.
        • Kontakt:
    • Kansas
      • Kansas City, Kansas, Vereinigte Staaten, 66160
        • Rekrutierung
        • University of Kansas Medical Center (KUMC) - School of Medicine - Parkinson's Disease and Movement D
        • Kontakt:
        • Hauptermittler:
          • Rajesh Pahwa, M.D.
    • Michigan
      • Farmington Hills, Michigan, Vereinigte Staaten, 48334
        • Rekrutierung
        • Quest Research Institute
        • Hauptermittler:
          • Aaron Ellenbogen, D.O.
        • Kontakt:
    • New York
      • New York, New York, Vereinigte Staaten, 10019
        • Rekrutierung
        • Mount Sinai Hospital
        • Hauptermittler:
          • Joohi Jimenez-Shahed, M.D.
        • Kontakt:
    • North Carolina
      • Durham, North Carolina, Vereinigte Staaten, 27710
        • Rekrutierung
        • Duke Department of Neurosurgery
        • Hauptermittler:
          • Kyle Mitchell, M.D.
        • Kontakt:
    • Ohio
      • Columbus, Ohio, Vereinigte Staaten, 43210
        • Rekrutierung
        • The Ohio State University Wexner Medical Center
        • Hauptermittler:
          • Zachary Jordan, M.D.
        • Kontakt:
    • Oklahoma
      • Tulsa, Oklahoma, Vereinigte Staaten, 74136
        • Rekrutierung
        • The Movement Disorder Clinic of Oklahoma
        • Kontakt:
        • Hauptermittler:
          • Kevin Klos, M.D.
    • Pennsylvania
      • Willow Grove, Pennsylvania, Vereinigte Staaten, 19090
        • Rekrutierung
        • Abington Neurology
        • Hauptermittler:
          • David Weisman, M.D.
        • Kontakt:
    • South Carolina
      • Charleston, South Carolina, Vereinigte Staaten, 29401
        • Rekrutierung
        • Medical University of South Carolina (MUSC) - The Murray Center for Research on Parkinson's Disease
        • Kontakt:
        • Hauptermittler:
          • Vanessa Hinson, M.D., PhD
    • Tennessee
      • Cordova, Tennessee, Vereinigte Staaten, 38018
        • Rekrutierung
        • Neurology Clinic, P.C.
        • Kontakt:
        • Hauptermittler:
          • Kendrick Henderson, M.D.
      • Memphis, Tennessee, Vereinigte Staaten, 38157
        • Rekrutierung
        • Veracity Neuroscience LLC
        • Kontakt:
        • Hauptermittler:
          • Mark LeDoux, M.D., PhD
    • Texas
      • Round Rock, Texas, Vereinigte Staaten, 78681
        • Rekrutierung
        • Central Texas Neurology
        • Kontakt:
        • Hauptermittler:
          • Elizabeth Peckham, M.D.
    • Virginia
      • Charlottesville, Virginia, Vereinigte Staaten, 22903
        • Rekrutierung
        • University of Virginia Health System (UVAHS) - Adult Neurology Clinic
        • Hauptermittler:
          • Binit Shah, M.D.
        • Kontakt:
    • Washington
      • Spokane, Washington, Vereinigte Staaten, 99202
        • Rekrutierung
        • Inland Northwest Research
        • Hauptermittler:
          • Jason Aldred, M.D.
        • Kontakt:
    • Wisconsin
      • Milwaukee, Wisconsin, Vereinigte Staaten, 53226
        • Rekrutierung
        • Medical College of Wisconsin
        • Kontakt:
        • Hauptermittler:
          • Karen Blindauer, M.D.

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

40 Jahre bis 85 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. Diagnosis of idiopathic PD according to MDS Clinical Diagnostic Criteria for Parkinson's Disease (Postuma et al., 2015) and

    a. Cohort 1: Participated in a prior PD clinical trial with buntanetap. i. A legally authorized representative is required for any participant whose MMSE <21 at screening.

    b. Cohort 2: Has been receiving DBS treatment in either 1) the subthalamic nucleus or 2) the globus pallidus internus for at least 12 months after a successful DBS surgery that achieved the goal.

    i. Female or male adults aged 40 to 85 years. ii. H&Y stage 1-3 in ON state. iii. MMSE 21-30 at screening and baseline.

  2. Have a support person who will accompany the participant on study visits at designated times.

  3. Female participants of childbearing potential* must have a negative urine pregnancy test at screening, must be non-lactating, and must agree to use a highly effective method of contraception (i.e., a method resulting in a failure rate of less than 1% per year when used consistently and correctly) during the trial and for one month after the last dose of trial treatment, such as:

    1. Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,

    2. Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,

    3. Intrauterine device (IUD),

    4. Intrauterine hormone-releasing system (IUS),

    5. Bilateral tubal occlusion,

    6. Vasectomized partner (a vasectomized partner is a highly effective contraception method provided that the partner is the sole male sexual partner of the participant, and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used),

    7. Sexual abstinence (sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant).

      • Non-childbearing potential includes surgically sterilized or postmenopausal with no menstrual bleeding for at least one year prior to study start.

    Protocol ANVS-25002 Ver. 2.1; 09-23-2025 Confidential Page 30 of 54

  4. Male participants must be sterile or sexually inactive or agree not to father a child during the study and one month after the last dose of study medication and must agree to use a barrier method for contraception. Female partners of male participants must adopt a highly effective method of contraception with a failure rate of less than 1% per year when used consistently and correctly such as:

    1. Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,
    2. Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,
    3. IUD,
    4. IUS,
    5. Bilateral tubal occlusion.
  5. No evidence of current suicidal ideation or previous suicide attempt in the past month as evaluated in the C-SSRS.

  6. Stability of permitted medications for at least 4 weeks prior to screening. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

    1. Standard of care anti-parkinsonian medication,
    2. Cholinesterase inhibitors and/or memantine medication,
    3. Anticonvulsant medications used for epilepsy or mood stabilization, or neuropathic pain indications, and have not had a breakthrough seizure 3 years prior to screening,
    4. Mood-stabilizing psychotropic agents including, but not limited to, lithium,
  7. Adequate visual and hearing ability (physical ability to perform all the study assessments).

  8. Good general health with no disease expected to interfere with the study.

Exclusion Criteria:

  1. Cohort 1 only: Is currently receiving DBS treatment. (Participant may enroll in Cohort 2 if they meet the corresponding inclusion/exclusion criteria).

  2. A history of psychiatric disorder such as schizophrenia, bipolar disorder, or major depression according to the criteria of the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM), unless their symptoms have been mild, and they are stable on treatment or no longer need treatment. Mild depression or history of depression that is stable on treatment with selective serotonin reuptake inhibitors (SSRI) or serotonin and norepinephrine reuptake inhibitors (SNRI) medication at a stable dose is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

  3. A history of seizure disorder. If stable on medication, it is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

  4. A history or current evidence of long QT syndrome, Fridericia's formula corrected QT (QTcF) interval ≥ 450 ms for men and ≥ 460 ms for women, or torsades de pointes.

  5. Bradycardia (<50 bpm) or tachycardia (>100 bpm) on the ECG at screening and deemed medically significant by the PI.

    Protocol ANVS-25002 Ver. 2.1; 09-23-2025 Confidential Page 31 of 54

  6. Uncontrolled Type-1 or Type-2 diabetes. A participant with hemoglobin subunit alpha 1c (HbA1c) levels up to 7.5% can be enrolled if the investigator believes the participant's diabetes is under control.

  7. Clinically significant renal (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] <50 mL/min/BSA [body surface area]) or hepatic impairment (Alkaline phosphatase [ALP] > 2.0X the upper limit of normal [ULN] and/or total bilirubin > 2.0X ULN).

  8. Any clinically significant abnormal laboratory values. Participants with liver function tests (aspartate aminotransferase [AST] or alanine aminotransferase [ALT]) greater than twice ULN will be excluded.

  9. Is at imminent risk of self-harm, based on clinical interview and responses on the C-SSRS, or of harm to others in the opinion of the investigators. Participants must be excluded if they report suicidal ideation with intent, with or without a plan or method (e.g., positive response to Items 4 or 5 in assessment of suicidal ideation on C-SSRS) in the past 2 months, or suicidal behavior in the past 6 months.

  10. Cancer or has had a malignant tumor within the past year, except participants who underwent potentially curative therapy with no evidence of recurrence (participants with stable untreated cancer are not excluded).

  11. Alcohol / Substance use disorder, moderate to severe, in the last 5 years according to the most current version of the DSM.

  12. Participation in another clinical trial with an investigational agent and have taken at least one dose of study medication, unless unblinded on placebo, within 4 weeks prior to the start of screening, or five half-lives of the investigational drug, whichever is greater. The end of a previous investigational trial is the date the last dose of an investigational agent was taken.

  13. A learning disability or developmental delay.

  14. Participants whom the site PI deems to be otherwise ineligible.

  15. A known allergy to the investigational drug or any of its components.

    Inactive ingredients of the investigational medicinal product:

    • Silicified microcrystalline cellulose
    • Dibasic calcium phosphate dihydrate
    • Mannitol
    • Stearic acid
    • Hypromellose (capsule shells structure)
    • Titanium dioxide (opacifier of the capsule shells)
  16. Is currently pregnant, breast-feeding, and/or lactating.

  17. Uncontrolled hypertension (systolic >160mmHg and/or diastolic >95mmHg) or hypotension (systolic <90mmHg and/or diastolic <60 mmHg) and deemed medically significant by the PI.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Nicht randomisiert
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Cohort 1 - buntanetap

Cohort 1 will enroll via invitation only for PD participants who have previously participated in bun

buntanetap capsules 30 mg by mouth daily

Experimental: Cohort 2 - buntanetap

Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment.

buntanetap capsules 30 mg by mouth daily

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Safety of buntanetap
Zeitfenster: 36-months of treatment

Safety assessments of participants with PD receiving treatment with buntanetap

36-months of treatment
Adverse Events (AE)
Zeitfenster: 36-months of treatment

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention

36-months of treatment
Treatment Emergent Adverse Events (TEAE)
Zeitfenster: 36-months of treatment

TEAE is an event that emerges during treatment, having been absent pretreatment, or worsens relative to the pretreatment state

36-months of treatment
Serious Adverse Events (SAE)
Zeitfenster: 36-months of treatment

SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization, or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a birth defect or congenital anomaly

36-months of treatment

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Laurie Sanders, Ph.D., Duke Clinical Research Institute

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

9. Januar 2026

Primärer Abschluss (Geschätzt)

1. September 2029

Studienabschluss (Geschätzt)

1. November 2029

Studienanmeldedaten

Zuerst eingereicht

26. November 2025

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

9. Dezember 2025

Zuerst gepostet (Tatsächlich)

16. Dezember 2025

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

30. Oktober 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

28. Oktober 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

UNENTSCHIEDEN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren